ViGenCell NK/T-Cell Lymphoma Drug Designated for Expedited Review by MFDS
- Input
- 2026-11-17 15:02:05
- Updated
- 2026-11-17 15:02:05

ViGenCell said on the 17th that VT-EBV-N, an antigen-specific T-cell therapy being developed to treat Epstein-Barr virus (EBV)-positive extranodal NK/T-cell lymphoma, had been designated an advanced biopharmaceutical eligible for expedited processing by the MFDS. The designation came about five months after the company applied in June.
The designation applies to drugs and other products developed to treat severe or rare diseases for which there are no alternative treatments, or that are life-threatening. Designated products can receive tailored reviews from a dedicated review team and priority review, and also become eligible to apply for conditional marketing authorization.
Conditional marketing authorization is a system under which a drug that has demonstrated a certain level of efficacy in clinical trials is authorized on the condition that additional clinical trials, among other things, are conducted after it goes on the market. This allows authorization to be pursued before confirmatory clinical trials are completed, potentially shortening the development and launch timelines for treatments for severe and rare diseases. Priority review aims to complete reviews within 90 working days, fewer than the 120 working days for standard applications.
VT-EBV-N recorded a 95.0% disease-free survival (DFS) rate, its primary endpoint, in a Phase 2 trial. The treated group also maintained an overall survival (OS) rate of 100% at four years of follow-up. The clinical trial results were presented orally this year at the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA).
ViGenCell plans to prepare for conditional marketing authorization in South Korea following the designation while also pursuing global technology-transfer discussions. VT-EBV-N was designated an orphan drug during development by the MFDS in 2019.
The process of administering the treatment to patients in South Korea is also under way. In April, VT-EBV-N received a favorable decision from the Ministry of Health and Welfare’s Committee for Advanced Regenerative Medicine and Advanced Biopharmaceuticals, and in September it received approval from the ministry for the country’s first advanced regenerative medicine treatment plan. ViGenCell plans to administer the treatment to patients through Yeouido St. Mary’s Hospital of the Catholic University of Korea within the year.
ViGenCell CEO Gi Pyeong-seok said, “We will use the shortened review process made possible by the designation to prepare for conditional marketing authorization and accelerate our global technology-transfer discussions.”
[email protected] Jung Sang-hee Reporter